May 2025
Optimizing Healthcare Outcomes: Clinical Advancements, Economic Impact of RYONCIL® in Treating Pediatric SR-aGVHD
A Science & Innovation Webinar, presented by Mesoblast.
Join us for an insightful webinar on the advancements in treating pediatric steroid-refractory acute versus host disease (SR-aGVHD) with RYONCIL®, which was approved by the FDA on December 19, 2024. We will delve into the significant unmet need in SR-aGVHD, a condition with high morbidity and mortality rates, and how Ryoncil’s safety and efficacy offers a promising new therapeutic option that has significant impact on long-term survival outcomes. We will also explore the potential to deliver significant healthcare cost savings due to substantial long-term survival benefits, utilizing health economic models for ultra-rare diseases and high-impact therapies.
April 2025
AMCP Market Insights: Webinar on ER+/HER2- Metastatic Breast Cancer
An AMCP Market Insights Webinar.
Join us for a webinar on ER+/HER2- Metastatic Breast Cancer, a disease affecting nearly 150,000 people in the U.S. Despite advancements in treatment, significant gaps remain in access, affordability, and comprehensive care. This session will feature a clinical key opinion leader and payer participants from the roundtable convened by AMCP in February 2025. Presenters will characterize the clinical and QOL burden of ER+/HER2, explore the mechanisms of action of current therapies, review current treatment options, describe therapeutics that targets ERs, and outline payer strategies to facilitate precision oncology care.
April 2025
Unpacking the Trump Drug Pricing Executive Order
In this hour-long webinar, health care attorney Ross Margulies of Manatt, Phelps & Phillips, LLP will review the scope of the April 15th drug pricing executive order and its impact across various health care stakeholders. We will dive into the background and history of the proposals, many of which are being resurfaced from the first Trump Administration, and talk through the pathway and prospects for these policy proposals.
MEMBERS
April 2025
Encore Presentation: GLP-1s for Everything! A Review of the Body of Evidence and Implications for Managed Care
You get a GLP-1! You get a GLP-1! Everyone gets a GLP-1! This encore presentation of the keynote session at AMCP 2025 delves into the transformative potential of GLP-1 receptor agonists (GLP-1RAs) across a wide range of conditions, including obstructive sleep apnea, binge eating disorder, substance use disorder, NASH, heart failure, osteoarthritis, cystic fibrosis, PCOS, and neurocognitive disorders like Parkinson's and Alzheimer's dementia. Attendees will gain insights into the latest advancements in the GLP-1RA pipeline and explore emerging therapies and their potential to reshape treatment paradigms.
Additionally, this discussion will address key implications for managed care and highlight the challenges in formulary management and benefit design. Join us for an in-depth exploration of these innovative therapies and their potential to revolutionize care across diverse health conditions
MEMBERS
March 2025
AMCP 2025
Connect with over 4,000 managed care pharmacy professionals from health plans, PBMs, pharma, and beyond. Gain valuable insights through cutting-edge education sessions, earn continuing education (CE) credits, and explore emerging trends and strategies. Registration opens for AMCP 2025 in Houston on Dec. 10 for AMCP members and Dec. 12 for non-members.
Key dates:
- Early bird: Dec. 10–Jan. 7
- Advanced: Jan. 8–Feb 5
- Late Advanced/Onsite: Feb 7-April 3
- Call for Session Proposals Submission Portal Open Aug. 19–Sept. 23, 2024.
- Call for Poster Abstracts Submission Portal Open Aug. 19-Oct. 31, 2024.
Stay and Save!
Registered attendees that book a hotel room in the AMCP hotel block will receive $100 off of current applicable registration fees (not applicable for student members).
March 2025
AMCP 2025 Pre-Conference Program: The Role of Artificial Intelligence (AI) in Revolutionizing Managed Care Pharmacy
As organizations look for ways to become more efficient and add value, they employ tools like Artificial Intelligence (AI) to help. Managed care pharmacy organizations are no different. They are embracing this technology to help with many tasks, such as underwriting, clinical decision-making, process optimization, and new product development. For managed care pharmacy professionals to stay current, there is a strong need to learn about these systems and how to embrace and use them to be more innovative and efficient in the future
This pre-conference program will feature managed care professionals utilizing AI in real-world applications within their organizations. It will also highlight companies on the leading edge of AI technology, developing solutions to the most vexing problems in pharmacy practice today.
This pre-conference program will conclude with a networking reception and hands-on demonstrations.
Please join us for this innovative exploration of the evolving world of AI.
MEMBERS
NON-MEMBERS
March 2025
UGN-102 Pre-Approval Information Exchange (PIE) Presentation
A Pre-Approval Information Exchange (PIE) Webinar sponsored by UroGen Pharma, Inc.
This webinar will be hosted by UroGen Pharma, Inc. and will discuss the disease state, product profile, commercialization plans, and clinical information for UGN-102. An investigational drug in development for the treatment of low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) in adult patients. The safety and efficacy of UGN-102 have not been established by the FDA. This presentation is intended for payors, formulary committees, and similar entities only.
This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions®.
This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.
March 2025
Regulatory Briefing: Marketplace Integrity and Affordability Proposed Rule
An AMCP Member Webinar
AMCP is excited to begin a new series of Regulatory Briefing webinars exclusively for AMCP members. Regulatory Briefings will provide an overview of newly proposed regulations and agency guidance relevant to managed care pharmacy. Each webinar will focus on a single rule, breaking down the changes proposed by the agency and any input that the agency is seeking.
In our first webinar, we will be looking at a newly proposed rule from CMS about the Affordable Care Act. Among the topics covered by the proposed rule are, enrollment periods, past due premiums, eligibility for enrollment in QHPs, and essential health benefits.
March 2025
Understanding the Devastating Impact of C3G and Primary IC-MPGN
A Science & Innovation Webinar, presented by Apellis.
Complement 3 Glomerulopathy (C3G) and Primary Immune Complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN) are two rare, chronic glomerular diseases caused by overactivation of the complement system resulting in severe kidney damage. Webinar topics will include the prevalence, characteristics, and unmet medical needs of patients living with these diseases.
March 2025
A Closer Look at Psoriasis, Beyond the Skin
A Science & Innovation Webinar, presented by Abbvie.
Psoriasis is a chronic, inflammatory, immunologic condition that primarily manifests on the skin, the body’s largest organ. If not properly treated, uncontrolled psoriasis can induce inflammatory processes beyond the skin and may lead to comorbid disease. Comorbidities that may impact psoriasis patients such as psoriatic arthritis (PsA), cardiovascular disease, metabolic syndrome, inflammatory bowel disease (IBD), depression and others add burden to the entire healthcare system and adversely impact patient outcomes.